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To investigate whether the use of long-acting BZs, in individuals aged 65 and over  is mediated by 6 
physical or psychological factors.  7 
 8 
Background 9 
Long-acting benzodiazepine (BZ) consumption among older people has implications for mortality, 10 
morbidity and cost-effective prescribing. Two models explain benzodiazepine use in this age group, 11 
one linked to physical illness and disability and one to psychological factors.  12 
 13 
Methods 14 
Secondary analysis of baseline data from a study of 1059 community-dwelling non-disabled people 15 
aged 65 years and over recruited from three general practices in London.  16 
For this analysis, use of long acting benzodiazepines was defined as any self-reported use of 17 
Diazepam or Nitrazepam in the last four weeks.  Associations between demographic factors, health 18 
service use, and  physical and psychological characteristics and benzodiazepine use were 19 
investigated .  20 
 21 
Findings 22 
The prevalence of benzodiazepine use in this sample was 3.3% (35/1059).  In univariate analyses, 23 
benzodiazepine use was associated with female gender, low income, high consultation rates, 24 
physical factors (medication for arthritis or joint pain, polypharmacy, difficulties in instrumental 25 
activities of daily living, recent pain) and psychological factors ((poor self-perceived health, social 26 
isolation, and symptoms of anxiety or agitation). In a multivariate logistic regression analysis only 27 
two factors retained statistically significant independent associations with benzodiazepine use: 28 
receiving only the state pension (OR = 4.0, 95% CI: 1.70, 9.80) and pain in the past 4 weeks (OR = 29 
3.79, 95% CI: 1.36, 10.54). 30 
 31 
Keywords : older people; benzodiazepines; pain; depression;  32 
 33 
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In older people, use of long acting benzodiazepines are associated with multiple risks, including falls, 2 
drowsiness and ataxia, cognitive decline, impaired psychomotor function, and risk of dependence 3 
(Voyer et al 2010) .  Older adults tend to take long acting benzodiazepines for longer, risking 4 
accumulation and potentiation of their sedative side effects.  The ageing population and 5 
polypharmacy with risks of adverse drug effects and drug induced iatrogenesis are contributing to 6 
increased demands on the UK National Health Service (NHS). Although long-term use of 7 
benzodiazepines has been discouraged now for some time (Leipzig et al 1999) , their use continues 8 
to be a problem. Therefore, it is vital to ensure benzodiazepine drugs are prescribed appropriately, 9 
and for the shortest duration clinically indicated. 10 
 11 
Some  epidemiological studies of benzodiazepine use in older adults suggest it reflects psychological 12 
disorder including depression, suicidal ideation, panic disorder,  anxiety, memory impairment, 13 
poorer self-rated health and poorer life satisfaction (Kirby et al 1999, Balastrieri et al 2005, Stowell 14 
et al 2008, Voyer et al 2009, Assem-Hilger et al 2009, Rikala et al 2011) , while others suggest it  15 
reflects physical illness and disability such as coronary heart disease, hypertension, pain related joint 16 
complaints, smoking, cancer, COPD, diabetes and multimorbidity (Dealberto et al 1997, Gleason et al 17 
1998, Fourrier et al 2001, Luijendijk et al 2008, Cheng et al 2008, van Eijk et al 2010) . Most studies 18 
show higher use in females(Kirby et al 1999, Jorm et al 2000, Windle et al 2007, Cheng et al 2008, 19 
Fourrier et al 2001) but  Mayer-Oakes et al.(1993)  and Swartz et al.(1991) showed that use of 20 
benzodiazepines was not associated  independently with gender, but with physical health status, 21 
which was poorer in women than men.   22 
 23 
General practitioners managing older people are often faced with the dilemma of treating a 24 
symptom or seeking the underlying cause. Knowing more about the reasons behind the use of 25 
benzodiazepines by older adults may help develop more appropriate alternative management 26 
strategies. Two explanatory models of benzodiazepine use among older adults – the psychological 27 
and the physical described above - deserve further investigation. This study aimed to explore the 28 
prevalence and characteristics of long-acting benzodiazepine use in a cohort of community-dwelling 29 
patients aged 65 years and older and their relationships to the two models. We hypothesized that 30 
long-acting benzodiazepine use in the sample population would be associated with physical factors 31 
such as arthritis, difficulties in IADL, polypharmacy or pain, or with psychological factors such as 32 
depression, anxiety, poor self-perceived health, social isolation, and impaired memory. Following the 33 
epidemiological literature, we also hypothesised that female gender, lower educational attainment 34 
3 
 
and increased service use would be positively associated with long-acting benzodiazepine use. 1 






Three large group practices in suburban London were recruited to participate in a multi-centre, 2 
multinational randomised controlled trial investigating the effect of Health Risk Appraisal for Older 3 
persons (HRA-O) on health behaviours and status (Stuck et al 2002) . Practices located in suburban 4 
London, particularly interested in primary care for older people, and using electronic medical 5 
recording systems in clinical encounters were purposively selected.  A full account of the 6 
methodology of the study is available elsewhere (Stuck et al 2007) , including practice size, 7 
recruitment of practices and patients, training of general practitioners in health promotion with 8 
older people, response rates, use of reminders and the evidence justifying the preventive care 9 
recommendations given. This study was part of a three nation RCT of health promotion for older 10 
people, and had data capture tools that reflected the consensus of opinion about salient clinical 11 
problems. 12 
 13 
To identify eligible patients aged 65 years and over, practice lists were cleaned by general 14 
practitioners. Eligibility criteria were: those living at home, without a) evidence of need for human 15 
assistance in basic activities of daily living, b) high dependency due to major physical or psychiatric 16 
illness, or cognitive impairment, or c) a terminal illness. Patients also had to have a sufficient 17 
understanding of English to complete the questionnaires. This patient population was further 18 
characterised using the Probability of Recurrent Admissions (Pra) questionnaire (Pacala et al 1995), 19 
and asked to complete a consent form by post. The Pra measures risk of hospital admission, and 20 
stratifies the population by level of risk for future in-patient care. It was used in the main study as 21 
the basis for risk-stratified outcome and analyses.  22 
 23 
Eligible and consenting patients were posted the HRA-O questionnaire.  The HRA-O is a 24 
multidimensional, self-completion questionnaire collecting information on health, functional status, 25 
health behaviours, preventive care, and psychosocial factors in older people (Table 1). The 26 
development  of the HRA-O questionnaire, the derivation of the instruments used in it, the exact 27 
definitions of the categories and the feasibility of its use in British primary care have been reported 28 
elsewhere (Iliffe et al 2005) . Non-responders to the initial mailing were sent a postal reminder. 29 
Those who responded, and those who met the inclusion criteria described above, were included in 30 
the study. The findings reported in this paper are from the baseline completion of the questionnaire. 31 
We analysed data from participants who reported using two named long-acting benzodiazepines 32 
(Diazepam or Nitrazepam) in the preceding 4 weeks. Long acting benzodiazepines (rather than short-33 
acting ones) were selected because of the high levels of risk associated with their use, including 34 
daytime sedation, cognitive and psychomotor impairment, increased risk of falls and fractures, and 35 
respiratory depression, particularly in older people (Mendelson 1992). 36 
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. These two long acting benzodiazepines were in common use in the UK at the time of data collection 1 
and are still prescribed today.  Both the brand and generic names of the drug were included in the 2 
questionnaire.  3 
At base-line, self-reported information on income (state pension only, versus more than state 4 
pension) was used as a measure of socio-economic status. Service use was recorded based on self-5 
reported number visits to the doctor in prior 12 months).  6 
 7 
The following physical characteristics were measured at base-line: assistance with more than one 8 
Lawton’s Instrumental Activities of Daily Living (Lawton & Brody 1969) , polypharmacy (number of 9 
prescription medications) and physical activity by the Physical Activity Scale for the Elderly score 10 
(Washburn et al 1993). Pain experience was measured using the Geriatric Pain Measure, a 24-item 11 
multidimensional pain questionnaire that uses a 10-point modified Likert scale and also captures the 12 
impact of pain on everyday living (Ferrell et al 2000) . 13 
 14 
The following psychological factors were measured at base-line: social isolation was measured 15 
according to the Lubben Social Network Scale (Lubben et al 2006), and depressed mood was 16 
ascertained with the 5-item Mental Health Inventory Screening Test (MHI-5) (Sherbourne & Stewart 17 
1999), one of the subscales of the Short Form-36 (SF-36), and asks questions about how the person 18 
felt during the past month. A score ≤ 65 indicated a depressed mood.  19 
  20 
Data were analysed using SPSS (version 19) for windows to carry out univariate and binary logistic 21 
regression analyses as appropriate.  In the first stage, χ 2 tests were used to explore the associations 22 
between any benzodiazepine use in the previous 4 weeks and the characteristics listed in Table 1. In 23 
the second stage of analysis, the variables significantly associated with the use of benzodiazepines in 24 







In all, 1059 patients aged 65 years and over were included across the three practices. Thirty five 2 
patients reported using a long-acting benzodiazepine (11 Nitrazepam, 24 Diazepam)  in the 3 
preceding 4 weeks, a prevalence of 3.3% (35/1059). Table 1 shows the associations between the 4 
selected HRA-O domains and long-acting benzodiazepine use.  5 
 6 
Table 1 near here 7 
 8 
Long-acting benzodiazepine users were significantly more likely to be female (28, 80%). They were 9 
also more likely to have visited the doctor more than 6 times in the past year (21,60%) versus 14 10 
,47%)), being in receipt of only the state pension (22,(62%) versus 13, 38%),and be taking medication 11 
for arthritis/joint pain ≥ 3 times/ week (15, 44% versus 7, 21%),. No statistically significant 12 
differences were found in age or educational attainment. 13 
 14 
Long-acting benzodiazepine users were significantly more likely to report needing help with 15 
instrumental activities of daily living (IADL) (63% versus 34%), have poorer self-perceived health 16 
(43% versus 21%), higher risk of social isolation (26% versus 14%), report pain in the previous four 17 
weeks (81% versus 39%), and scored lower on the mental mood screen (29% versus 13%). Six 18 
percent of benzodiazepine users stated they often or always experienced symptoms of depression or 19 
feeling low, compared to 2% of non benzodiazepine users. Three percent of patients using long-20 
acting benzodiazepines stated they often or always experienced symptoms of anxiety or agitation, 21 
compared to 1.5% of non benzodiazepine users. Long-acting benzodiazepine users were more likely 22 
to have poorer self-perceived health (43% versus 21%), higher risk of social isolation (26% versus 23 
14%), report pain in the previous four weeks (81% versus 39%), and scored lower on the mental 24 
mood screen (29% versus 13%). No difference was found according to cognitive impairment.  25 
 26 
In multivariate analysis (see Table 1) only two factors remained significantly associated with use of 27 
long-acting benzodiazepines; higher socioeconomic status as determined by receiving more than 28 





The prevalence of use of Diazepam and Nitrazepam in this sample of older adults is 3.3%. Long-2 
acting benzodiazepine use in this sample of older people is not independently associated with 3 
physical factors such as arthritis, difficulties in IADL or polypharmacy, or with psychological factors 4 
such as depression, anxiety, poor self-perceived health, social isolation, and impaired memory. It is 5 
independently associated with low income and pain, particularly pain which causes depressive 6 
symptoms.   7 
The use of long-acting benzodiazepines in our sample population appears related to a socio-8 
economic factor - pension level  and also to a physical symptom – pain. It raises the question 9 
whether in such cases treating the cause of pain in the form of pain-specific treatment approaches, 10 
would be more appropriate than using benzodiazepines.   11 
 12 
Strengths and Limitations of the study 13 
This was an in depth study of community dwelling older adults in an area which is surprisingly under-14 
researched. However, the prevalence of patients using long-acting benzodiazepines in this 15 
community-dwelling was 3.3%, which is lower of that found in many (but not all) studies in other 16 
Western countries. The findings therefore need to be treated tentatively. This low prevalence may 17 
be attributable to the fact that long-term benzodiazepine use has been actively discouraged for 18 
some time now in the UK, particularly in older adults, and so represents a success story for general 19 
practice.  It may also reflect the self-selected nature of the patients in the sample, who had joined a 20 
trial on health promotion, or self-selection by high-performing general practices with a special 21 
interest in health promotion in older people.   22 
Secondly, due to the cross-sectional nature of the data, it is not possible to establish causality in the 23 
relationships between long acting benzodiazepine use and the factors associated with it. Also, the 24 
number of cases and the number of variables in the statistical model may have resulted in the 25 
exclusion of some variables that would have been independently associated in a larger sample. 26 
Third, there are some limitations related to the generalizability of the findings of this study to other 27 
populations. The sample was drawn from three general practices in suburban London with a 28 
predominantly white population, the results of which may differ from that of rural general practice 29 
patients, ethnic minorities or institutionalised patients. We cannot rule out a selection bias in 30 
recruitment of older people who may be more motivated to return lengthy questionnaires. The 31 
question related to long-acting benzodiazepine use covered only the preceding four weeks and thus, 32 
we may have missed patients who had recently discontinued, and we could not distinguish between 33 
short-term and long-term users. We did not have information on whether the prescription was 34 
8 
 
written by the patient’s GP, psychiatrist or other specialist, the dosage, quantity, time point in the 1 
course of long-acting benzodiazepine treatment and total duration prescribed, indications and 2 
proportion of medication used as regular and ’ as needed’ use.  Only the use of long acting 3 
benzodiazepines (diazepam and nitrazepam) was examined, and short acting benzodiazepines were 4 
not included. Over against these limitations, the study had access to a relatively large sample size 5 
with homogeneity in many characteristics including age and background, and a high response rate, 6 
strengthening its internal validity.  7 
 8 
Comparison with existing literature 9 
Most other studies have included a wider range of benzodiazepines than we did. In 1999 in Ireland, 10 
Kirby et al. found prevalence rates of 17.3% for subjects of a similar age group to our study (Kirby et 11 
al 1999).  A French study (Fourrier et al 2001) in 2001 revealed that 32% of its 2972 community 12 
dwelling subjects were using benzodiazepines at baseline. In Sweden, Johnell et al. in (2009) 13 
reported that 25% of patients aged 75 or over used one or more, and 5% used two or more 14 
benzodiazepines and benzodiazepine related drugs .  More recently a Finnish study based on data 15 
collected from the population-based GeMS (Geriatric multidisciplinary strategy for the good care for 16 
the Elderly) project, analysed data from 700 participants aged 75 and over and found a baseline 17 
prevalence rate of 31% at baseline, of which 55% reported continued use in three further follow-ups 18 
(Rikala et al 2011).  Our findings are consistent with those of population-based studies from several 19 
countries which suggest rates of benzodiazepine use range from 3 to 17%   with rates typically higher 20 
among older than younger people (Cunningham et al 2010). In a study conducted in UK Primary care, 21 
De Wilde et al (2007 found that although 5.2% of older adults were still receiving benzodiazepines in 22 
2003, prescription of benzodiazepines had fallen by a third from 79.3 per 1000 in 1994 to 52.4 per 23 
1000 in 2003.  24 
 25 
When Luijendijk et al.(2008) studied determinants of long-term benzodiazepine use, they found pain 26 
from joint disorders also increased the risk of long-term benzodiazepine use.  People with lower 27 
socio-economic status receive a higher number of prescriptions than do those of higher socio-28 
economic status (van Eijk et al 2010). Furthermore, Odubanjo et al (2004) compared the quality of 29 
prescribing between a primary care cohort of 66 521 relatively deprived and 28 534 affluent patients 30 
over 70 years old in Ireland and found a statistically significant higher percentage of the deprived 31 
cohort were prescribed a long acting benzodiazepine drug. This finding is consistent with the findings 32 




Implications for future practice and research 1 
Inappropriate use of benzodiazepines remains a concern, internationally  (Campanelli 2012, Olfson 2 
2015, Préville 2012).  The findings of this study support the recommendation made elsewhere that 3 
primary care practitioners should enquire routinely about pain when seeing older adults in general 4 
practice (Carmaciu et al 2007). Good management of pain may avoid inappropriate use of long-5 
acting benzodiazepines and reduce the risks of their associated morbidities.  Future research could 6 
include analysis of a larger data set to explore further the relationship between pain and specific 7 
long-acting benzodiazepine use, and also explore the relationships between shorter-acting 8 
benzodiazepines (and newer equivalents) and pain. 9 
 10 
Conclusion 11 
A multidimensional approach to assessing and managing the circumstances and symptoms 12 
associated with potentially inappropriate benzodiazepine use appears justified in community-13 
dwelling older people. Appropriate treatment of pain may further reduce the use of benzodiazepines 14 
in older patients. 15 
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 30 
Table 1:  Factors associated with use of long-acting benzodiazepines : univariate analysis and multivariate logistic regression analysis  
Factor  n   (%) Unadjusted OR 95% CI p value Adjusted OR 95% CI p value 
Demographics 
Female n=583 
Male  n=476 
28   (5.0) 
 7   (1.4) 
3.380 1.463-7.809 0.003 2.003 0.684-5.861 0.20 
Receives solely the state pension  n=343 
Receives more than state pension  n=701 
21   (6.0) 
13   (1.8) 
3.448 1.706-6.993 0.001 4.081 1.698-9.804  0.002 
Basic education only* n=629 
More than basic education   n=424 
16  (2.6) 
18  (4.2) 
0.597 0.301-1.185 0.14    
Age 75 or more   n=463 
65-74 years old n=596 
20  (4.3) 
15  (2.5) 
1.749 0.885-3.454 0.12    
Service use        
6 or more consultations in past 12/12   n=215 
Up to 5 consultations in past 12/12  n=823 
14 (6.5) 
21  2.6 
2.730 1.364-5.462 0.006 2.292 0.883-5.950 0.09 
Physical        
Taking medicine for joint pain ≥3 times/week n=219 
Taking medicine for joint pain <3 times/week n=790 
15  (6.8) 
19  (2.4) 
2.984 1.490-5.975 0.002 0.665 0.236-1.872 0.40 
4 or more repeat prescription medications  n=357 
Up to 3 repeat medications n=686 
16  (4.5) 
19  (2.8) 
1.166 1.031-1.319 0.01 1.028 0.852-1.240 0.77 
Diagnosis of Arthritis/rheumatism n-430 
No diagnosis of arthritis/rheumatism  n= 609 
19  (4.4) 
14  (2.3) 
1.965 0.974-3.963 0.06    
Difficulties in IADL  n=361 
No IADL difficulties  n=663 
20  (5.5) 
12 (1.8) 
3.182 1.537-6.587 0.002 1.888 0.739-4.821 0.18 
Pain in past 4 weeks 25 (6.2) 6.544 2.660-16.103 <0.001 3.787 1.361-10.542 0.01 
Psychological        
Symptoms of depression/feeling low  n=116 
No depression/low symptoms  n= 907 
10  (8.6) 
23  (2.5) 
1.525 1.153-2.017 0.003 1.287 0.846-1.957 0.24 
Depression (Mental mood screen)  N=150 
Negative mental mood screen  n=888 
10  (6.7) 
24  (2.7) 
2.622 1.232-5.581 0.01 0.843 0.264-2.693 0.77 
Fair or Poor self perceived health  n=229 
Good or excellent self perceived health  n=823 
15  (6.6) 
20  (2.4) 
2.814 1.417-5.590 0.003 1.246 0.459-3.382 0.67 
Socially isolated  n=146 
Not socially isolated  n= 902 
9   (6.2) 
26  (2.9) 
2.213 1.016-4.824 0.05 1.715 0.595-4.946 0.32 
Symptoms of anxiety/agitation 16 (5.2) 1.440 1.065-1.947 0.02 1.287 0.846-1.957 0.24 
Table
Impaired memory  n=102 
No memory impairment  n=921 
3   (2.9) 
32  (3.5) 
0.845 0.254-2.809 0.78    
        
IADL= Instrumental activities of daily living 
* basic education only = left school at or before 16 
